Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BAY2402234||BAY-2402234|BAY 2402234||BAY2402234 is a small molecule inhibitor that selectively binds to and inhibits dihydroorotate dehydrogenase (DHODH), which induces differentiation of blast cells and potentially leads to cell cycle arrest, decreased proliferation, increased apoptosis, and tumor growth inhibition (PMID: 30940908).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||BAY2402234||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, BAY2402234 treatment induced differentiation, cell cycle arrest and apoptosis, and inhibited proliferation of acute myeloid leukemia cell lines in culture, and induced differentiation, reduced tumor burden and increased survival in cell line and patient-derived xenograft (PDX) models (PMID: 30940908).||30940908|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03404726||Phase I||BAY2402234||A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies||Recruiting|